Abstract
Aging is associated with a reduced magnitude of primary immune responses to vaccination. mRNA-based SARS-CoV-2 vaccines have shown efficacy in older adults but virus variant escape is still unclear. Here we analyze humoral and cellular immunity against an early-pandemic viral isolate and compare that to the P.1 (Gamma) and B.1.617.2 (Delta) variants in two cohorts (<50 and >55 age) of mRNA vaccine recipients. We further measure neutralizing antibody titers for B.1.617.1 (Kappa) and B.1.595, with the latter SARS-CoV-2 isolate bearing the spike mutation E484Q. Robust humoral immunity is measured following second vaccination, and older vaccinees manifest cellular immunity comparable to the adult group against early-pandemic SARS-CoV-2 and more recent variants. More specifically, the older cohort has lower neutralizing capacity at 7-14 days following the second dose but equilibrates with the younger cohort after 2-3 months. While long-term vaccination responses remain to be determined, our results implicate vaccine-induced protection in older adults against SARS-CoV-2 variants and inform thinking about boost vaccination.
【초록키워드】 SARS-CoV-2, Efficacy, immune response, vaccination, Older adults, mRNA vaccine, aging, variant, SARS-CoV-2 variant, Delta, B.1.617.2, virus, variants, Humoral immunity, Cohort, Viral, SARS-CoV-2 variants, cellular immunity, spike mutation, mRNA, P.1, B.1.617.1, immune responses, Gamma, age, neutralizing capacity, Antibody titers, boost, humoral and cellular immunity, Neutralizing antibody titer, humoral, Older, recipients, second vaccination, second dose, neutralizing antibody titers, while, mRNA-based SARS-CoV-2 vaccines, vaccinee, shown, reduced, magnitude, comparable, mRNA-based SARS-CoV-2 vaccine, vaccination response, 【제목키워드】 mRNA vaccination, immune response, SARS-CoV-2 variant, dose, Older,